Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is it reasonable to use hypofractionation in breast cancer patients with non-active connective tissue disorders?
Answer from: Radiation Oncologist at Academic Institution
Yes, it is reasonable to use hypofractionation in this patient panel. I have used the Canadian fractionation schedule several times in this scenario.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I’ve also routinely done this with no issue at all.
Sign in or Register to read more
15771
15793
Related Questions
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Do you recommend re-excision of a unifocal positive anterior margin at skin after lumpectomy in a patient with otherwise low risk breast cancer features?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
How would you treat a young breast cancer patient with limited nodal involvement and an isolated sternal oligometastasis at diagnosis?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?